Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs
Source: SeekingAlpha
2026-03-05 21:46:27 ET
More on Lineage Cell Therapeutics
- Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics
- Historical earnings data for Lineage Cell Therapeutics
- Financial information for Lineage Cell Therapeutics
Read the full article on Seeking Alpha
For further details see:
Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs
Lineage Cell Therapeutics, Inc.
NASDAQ: LCTX
LCTX Trading
-1.59% G/L:
$1.855 Last:
607,375 Volume:
$1.80 Open:
LCTX Latest News
March 05, 2026 04:01:00 pm
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026 08:00:00 am
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
January 29, 2026 01:31:00 pm
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
January 06, 2026 08:00:00 am
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
LCTX Stock Data
$424,954,306
168,599,757
0.11%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
Carlsbad
